Browse the evidence

Obesity treatment could generate a social return on investment of $3.81 per dollar nationally and $8.57 from states’ perspective.

Investing in obesity treatment can yield significant economic returns for states and the nation.

Obesity interventions generate substantial social value totaling $15 billion in net social value nationally.

Investing in obesity treatment can lead to significant societal benefits and economic value.

36.7% of adults with obesity but without diabetes had a prescription for semaglutide or tirzepatide that lasted less than 32 days.

Practitioners should be aware that a significant portion of patients may not adhere to GLP-1 RA prescriptions.

Persistent prescriptions (coverage for ≥336 days) were observed in 18.6% of participants.

A minority of patients may maintain long-term use of GLP-1 RAs, indicating potential for sustained treatment benefits.

The oleogel-in-oleogel system is capable of delivering fewer calories than fats and most oleogels while still providing essential fatty acids.

This could be a viable alternative for those looking to reduce caloric intake from fats.

Die aktuelle private Finanzierung von GLP-1-Rezeptoragonisten schränkt den Zugang für Menschen mit niedrigem sozioökonomischem Status ein.

Praktiker sollten die finanziellen Barrieren für den Zugang zu GLP-1-Rezeptoragonisten berücksichtigen.

Es gibt ethische Bedenken bezüglich der Verschiebung von Priorisierungen hin zu einer pharmakologischen Behandlung.

Praktiker sollten die ethischen Implikationen der Verschiebung hin zu pharmakologischen Behandlungen bedenken.

Future clinical trials are needed to clarify the mechanisms of benefit and define the role of weight-reduction therapies in obesity-related HFpEF.

Clinicians should be aware that ongoing research may further inform treatment strategies for obesity-related HFpEF.

Among patients who discontinued treatment, 72% did not demonstrate weight regain.

Clinicians may find that many patients can maintain weight after stopping GLP-1RA therapy.

Unerwünschte Wirkungen von Semaglutid sind gut dokumentiert, insbesondere gastrointestinale Beschwerden.

Ärzte sollten über die häufigsten Nebenwirkungen von Semaglutid informiert sein, um Patienten entsprechend zu beraten.

28.1% of eligible patients were current users of GLP-1 receptor agonists.

A notable proportion of eligible OSA patients are utilizing GLP-1 RAs, indicating potential treatment pathways.

Having Medicaid was associated with a lower likelihood of using GLP-1 receptor agonists among eligible patients.

Practitioners should be aware that socioeconomic factors, such as Medicaid coverage, may influence GLP-1 RA utilization.

There was no significant effect of whey or soy protein supplementation on lean body mass (LBM) or squat performance.

Practitioners should note that whey and soy protein may not significantly impact LBM or squat performance.

There is significant heterogeneity in the theoretical models and psychometric properties of existing tools assessing DEAB in athletes.

Practitioners should be cautious when interpreting results from various DEAB assessment tools due to their differing foundations and properties.

Resistance training frequency does not significantly affect changes in muscle mass.

Increasing resistance training frequency may not lead to greater muscle mass gains.

Supplementation often fails to improve protein balance or related physiological and performance outcomes under severe operational stress.

Practitioners should consider that protein supplementation may not be beneficial in high-stress operational environments.

In overweight and obese subjects undergoing a Mediterranean-type low-calorie diet, a different distribution of daily protein intake between meals and snacks does not result in significant differences in terms of fat mass loss and lean mass maintenance.

Practitioners can consider that protein distribution throughout the day may not significantly impact fat loss or muscle maintenance in similar dietary contexts.

Hepatocyte-specific ALOXE3 expression reduces weight gain and hepatic steatosis.

Enhancing ALOXE3 expression could be a strategy for reducing obesity-related liver issues.

Thiazolidinediones (TZDs) are associated with weight gain, limiting their use as first-line agents for type 2 diabetes.

Practitioners should be cautious in prescribing TZDs due to their association with weight gain.

The mortality of German type 2 diabetes (T2D) patients is approximately 3.1 times higher than that of the general population.

Healthcare providers should be aware of the significantly higher mortality risk in T2D patients compared to the general population.

The cardiovascular risk in the current DMP for T2D patients is not adequately addressed, indicating potential for improvement.

There is a need for healthcare systems to enhance cardiovascular care in T2D management programs.

Twenty percent of survey respondents had a high overall score on the Eating Attitudes Test (EAT-26), indicating high rates of disordered eating behaviors.

Practitioners should be aware of the prevalence of disordered eating in this population when addressing weight loss.

All interview participants reported engaging in and/or observing disordered eating behaviors in efforts to lose weight.

Understanding the social dynamics of disordered eating can inform interventions.

Disordered eating behaviors produced ripples of embodied experiences affecting family, friends, and coworkers of dieters.

Practitioners should consider the social context of disordered eating when developing support strategies.